Clinical Trials · NCT05333003
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
- Phase
- N/A
- Recruitment status
- Active Not Recruiting
- Sponsor
- Centre for Addiction and Mental Health
- Enrollment
- 92
- Start date
- May 2022
- Locations
- 1 site, Canada
- Primary endpoint
- Weight change